ALLO Allogene Therapeutics, Inc.
$1.21▼ -3.20%
Healthcare
Other
Volume 10.58M
Avg Volume (10D) 6.00M
Key Metrics & Fundamentals
Market Cap
$418.04M
P/E Ratio
–
Div Yield
0.00%
52W Range
1.04 - 4.46
% vs 50 MA
-28.30%
% vs 200 MA
-39.15%
RSI-14
23.9
MACD Histogram
+0.0000
Beta (1Y vs SPY)
1.88
Free Cash Flow
-$32.15M
Gross Rev
$4.64M
Gross Profit
$4.64M
EBITDA
-$39.69M
COGS
–
Operating Exp
$51.56M
Operating Income
-$46.92M
EBIT
-$46.92M
Pretax Income
-$42.68M
Net Income
-$42.68M
EPS (Diluted)
-0.13
Price & Volume History
Loading chart…
Recent News
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
GlobeNewswire · Oct 26, 2026 8:30 AM ET
CLLS Stock Heads For 14-Month Low After 40% Rout: Citizens Flags Delayed Cellectis Catalysts After Cancer Pipeline Pivot
Stocktwits · Sep 15, 2026 7:11 AM ET
Cellectis Shares Fall After Realigning Focus to Become in Vivo Gene Editing Company
MT Newswires · Sep 14, 2026 2:55 PM ET
Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound?
Zacks · Sep 11, 2026 11:30 AM ET
Allogene Therapeutics CFO Geoffrey Parker to Retire
MT Newswires · Sep 2, 2026 8:45 AM ET
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
BioPharma Dive · Sep 2, 2026 8:32 AM ET
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker
GlobeNewswire · Sep 2, 2026 8:30 AM ET
Allogene Therapeutics Announces Participation in September Investor Conference
GlobeNewswire · Aug 31, 2026 8:30 AM ET
Allogene (ALLO) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 19, 2026 4:58 PM ET
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
Zacks · Aug 17, 2026 9:40 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See ALLO's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.